Home > Healthcare > Drug Device Combination > Therapeutic Systems > Oncology Market

Oncology Market Trends

Report ID: GMI4879
Published Date: Apr 2023
Report Format: PDF

Download Free Sample

Oncology Market Trends

Side effects associated with oncology treatment such as chemotherapy can potentially hinder the growth of global industry. Patients undergoing chemotherapy may suffer from long-term damage to the heart, lungs, kidneys, or reproductive organs. This can occur after the treatment by damaging the healthy cells, thus limiting the industry progression. Moreover, certain types of chemotherapy drugs may cause delayed side effects. Few of the common side effects include hair loss, fatigue, anaemia, infections and easy bruising & bleeding among others, thereby hampering the overall market demand.

Authors: Mariam Faizullabhoy

Frequently Asked Questions (FAQ) :

The global market for oncology reached over USD 280 billion in 2022 and is anticipated to exhibit 9.7% CAGR from 2023-2032 due to increasing government support.

Hospitals will record over USD 462 billion by 2032 owing to the strong presence of highly trained professionals in these settings for handling advanced cancer diagnosis equipment.

North America held 46% of the oncology market share in 2022 on account of rising burden of cancer in the U.S.

GE Healthcare, F. Hoffmann-La Roche, Pfizer, Bayer AG, Merck & Co., Inc., Abbott, AbbVie Inc., Thermo Fischer Scientific, Siemens Healthineers AG, Amgen Inc., Astellas Pharma, Inc., and AstraZeneca are a few major oncology industry players.